The DOI matches its Crossref record; 32 of the 32 references it cites were found in a registry or an index.
Prognosis and Neuropathologic Correlation of Clinical Subtypes of Parkinson Disease
Open accessAbstract
Importance: Clinical subtyping of Parkinson disease at diagnosis is useful in estimating disease course and survival. Severity and rate of progression of neuropathologies are important determinants of clinical Parkinson subtypes. Objective: To provide longitudinal clinical disease-course data and neuropathologic correlation for newly proposed Parkinson disease subtypes. Design, Setting, and Participants: Retrospective cohort study of consecutive patients with autopsy-confirmed Parkinson disease who were regularly seen throughout their disease course by hospital specialists in the United Kingdom and donated their brain at death to the Queen Square Brain Bank between January 2009 and December 2017. Patients with additional neuropathologic diagnoses, monogenic forms of parkinsonism, or insufficiently detailed clinical information were excluded. Based on severity of motor symptoms, rapid eye movement sleep behavior disorder, and autonomic and cognitive function at diagnosis, patients were classified adapting a subtyping classification into mild-motor predominant, intermediate, or diffuse malignant subtypes. Main Outcomes and Measures: Time from diagnosis to disease milestones (recurrent falls, wheelchair dependence, dementia, and care home placement) and death were compared between subtypes, and their risk was estimated using Cox hazard regression models. Severity and distribution of Lewy pathology and Alzheimer disease-related pathology were assessed using staging systems. Results: From a total of 146 patients, 111 patients were included (67 men [60.4%]; mean [SD] age at diagnosis, 62.5 [11.5] years). The diffuse malignant subtype had earlier development of milestones and reduced survival. Cox proportional hazard regression showed an increased adjusted risk of any disease milestone (hazard ratio, 10.90; 95% CI, 5.51-21.58; P < .001) and death (hazard ratio, 3.65; 95% CI, 1.98-6.75; P < .001) in the diffuse malignant group. Age at diagnosis was the only additional variable with statistical significance (adjusted hazard ratio for death, 1.14; 95% CI, 1.11-1.17; P <.001). Staging of Lewy pathology and Alzheimer disease-related pathology did not differ between subtypes, although they showed different rates of progression, and the latter was associated with age at death. Conclusions and Relevance: Parkinson clinical subtypes at diagnosis may estimate disease course and survival, which may be useful in providing a more accurate prognosis in individual patients in clinical practice and helping to stratify subgroups in clinical trials. Different severity and progression of neuropathologies are important determinants of Parkinson subtypes, and age at diagnosis should be included in future subtype classifications.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The check wasn’t confident either way, so it gives no verdict — never disputed.
In the citing paper
“One barrier to the clinical implementation of passive digital biomarkers, however, has been the lack of computing resources for storing and automatically processing and analyzing the large amount of data collected from passive digital tools that continuously monitor behavior over long periods of time.120”
From Review of Artificial Intelligence for Clinical Use in Alzheimer's Disease and Related Dementias (2026) · cites this paper as [120]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Staging of brain pathology related to sporadic Parkinson’s disease
Braak, H., Tredici, K. D., Rüb, U., de Vos, R. A. I., Jansen Steur, E. N. H., & Braak, E. (2003) · Neurobiology of Aging · doi:10.1016/s0197-4580(02)00065-9 · Cited by 10,777
Mirra, S. S., Heyman, A., McKeel, D., Sumi, S. M., Crain, B. J., Brownlee, L. M., Vogel, F. S., Hughes, J. P., Belle, G. V., Berg, L., et al. (1991) · Neurology · doi:10.1212/wnl.41.4.479 · Cited by 4,961
Diagnosis and management of dementia with Lewy bodies: Fourth consensus report of the DLB Consortium
McKeith, I. G., Boeve, B. F., Dickson, D. W., Halliday, G., Taylor, J.-P., Weintraub, D., Aarsland, D., Galvin, J., Attems, J., Ballard, C. G., et al. (2017) · Neurology · doi:10.1212/wnl.0000000000004058 · Cited by 4,476
Systematic review of levodopa dose equivalency reporting in Parkinson's disease
Tomlinson, C. L., Stowe, R. L., Patel, S., Rick, C., Gray, R. G., & Clarke, C. E. (2010) · Movement Disorders · doi:10.1002/mds.23429 · Cited by 4,219
Phases of Aβ-deposition in the human brain and its relevance for the development of AD
Thal, D. R., Rüb, U., Orantes, M., & Braak, H. (2002) · Neurology · doi:10.1212/wnl.58.12.1791 · Cited by 3,490
Braak, H., Alafuzoff, I., Arzberger, T., Kretzschmar, H., & Del Tredici, K. (2006) · Acta Neuropathologica · doi:10.1007/s00401-006-0127-z · Cited by 3,172
Montine, T. J., Phelps, C. H., Beach, T. G., Bigio, E. H., Cairns, N. J., Dickson, D. W., Duyckaerts, C., Frosch, M. P., Masliah, E., Mirra, S. S., et al. (2012) · Acta Neuropathologica · doi:10.1007/s00401-011-0910-3 · Cited by 2,894
The Parkinson Progression Marker Initiative (PPMI)
MAREK, K. L., Jennings, D. L., Lasch, S., Siderowf, A. D., Tanner, C. M., Simuni, T., Coffey, C. S., Kieburtz, K. D., Flagg, E., Chowdhury, S., et al. (2011) · Progress in Neurobiology · doi:10.1016/j.pneurobio.2011.09.005 · Cited by 1,934
Improved accuracy of clinical diagnosis of Lewy body Parkinson’s disease
Hughes, A. J., Daniel, S. E., & Lees, A. J. (2001) · Neurology · doi:10.1212/wnl.57.8.1497 · Cited by 807
Self-citationClinical criteria for subtyping Parkinson’s disease: biomarkers and longitudinal progression
Fereshtehnejad, S., Zeighami, Y., Dagher, A., & Postuma, R. B. (2017) · Brain · doi:10.1093/brain/awx118 · Cited by 619
Flagged first, then by citations
Cited by
Sorted by citations
Items 101–200 of 332
From cause and effect to causes and effects
Sturmberg, J. P., & Marcum, J. A. (2023) · Journal of Evaluation in Clinical Practice · doi:10.1111/jep.13814 · Cited by 21
Refining the clinical diagnosis of Parkinson's disease
Mulroy, E., Erro, R., Bhatia, K. P., & Hallett, M. (2024) · Parkinsonism & Related Disorders · doi:10.1016/j.parkreldis.2024.106041 · Cited by 27
Plasma neurofilament light chain level and orthostatic hypotension in early Parkinson’s disease
Park, D. G., Kim, J. W., An, Y., Chang, J., & Yoon, J. H. (2021) · Journal of Neural Transmission · doi:10.1007/s00702-021-02423-y · Cited by 21
The longitudinal progression of autonomic dysfunction in Parkinson's disease: A 7-year study
Stewart, C. B., Ledingham, D., Foster, V. K., Anderson, K. N., Sathyanarayana, S., Galley, D., Pavese, N., & Pasquini, J. (2023) · Frontiers in Neurology · doi:10.3389/fneur.2023.1155669 · Cited by 20
Clinical Characterization of Parkinson's Disease Patients With Cognitive Impairment
Gozalbo, A. S., Rodríguez‐Blázquez, C., Forjaz, M. J., & Martínez‐Martín, P. (2020) · Frontiers in Neurology · doi:10.3389/fneur.2020.00731 · Cited by 23
Stereotyped Relationship Between Motor and Cognitive Metabolic Networks in Parkinson's Disease
Rus, T., Schindlbeck, K. A., Tang, C. C., Vo, A., DHAWAN, V. M., Trošt, M., & Eidelberg, D. (2022) · Movement Disorders · doi:10.1002/mds.29188 · Cited by 19
Wu, J., Qin, C., Cai, Y., Zhou, J., Xu, D., Lei, Y., Fang, G., Chai, S., & Xiong, N. (2023) · Annals of Translational Medicine · doi:10.21037/atm-22-5756 · Cited by 19
Zhu, S., Li, H., Huang, Z., Zeng, Y., Huang, J., Li, G., Yang, S., Zhou, H., Chang, Z., Xie, Z., et al. (2025) · npj Parkinson s Disease · doi:10.1038/s41531-024-00865-1 · Cited by 19
Zhou, C., Guo, T., Wu, J., Wang, L., Bai, X., Gao, T., Guan, X., Gu, L., Huang, P., Xuan, M., et al. (2021) · Journal of Parkinson s Disease · doi:10.3233/jpd-212720 · Cited by 19
Biological effects of pathologies in Lewy body diseases: why timing matters
Matar, E., & Halliday, G. M. (2025) · The Lancet Neurology · doi:10.1016/s1474-4422(25)00085-7 · Cited by 18
Recent advances in understanding and treatment of Parkinson’s disease
Tarakad, A., & Jankovic, J. J. (2020) · Faculty Reviews · doi:10.12703/b/9-6 · Cited by 18
Domotics, smart homes and Parkinson’s disease
Noyce, A. J. (2021) · UCL Discovery (University College London) · Cited by 18
Baba, T., Takeda, A., Murakami, A., Koga, T., Isomura, T., Mori, E., Hisanaga, K., Ugawa, Y., Hattori, N., Murata, M., et al. (2022) · EClinicalMedicine · doi:10.1016/j.eclinm.2022.101571 · Cited by 18
Heron, C. L., Horne, K., Macaskill, M., Livingstone, L., Melzer, T., Myall, D. J., Pitcher, T., Dalrymple-Alford, J., Anderson, T. J., & Harrison, S. D. L. (2024) · Neurology · doi:10.1212/wnl.0000000000209301 · Cited by 11
A multicenter longitudinal study of cholinergic subgroups in Parkinson disease
Bohnen, N. I., Roytman, S., van der Zee, S., Carli, G., Michalakis, F., Luker, A. T., Slingerland, S., Frey, K. A., Scott, P. J. H., Koeppe, R. A., et al. (2025) · Nature Communications · doi:10.1038/s41467-025-60815-0 · Cited by 21
Distinct cutaneous α-synuclein signatures in body-first and brain-first Parkinson’s disease subtypes
Liu, M., Wen, T., Luo, H., Yang, T., Kong, Y., Jin, Y., Li, L., Yuan, Y., Liu, X., Yuan, J., et al. (2025) · Brain · doi:10.1093/brain/awaf395 · Cited by 18
Marsili, L., Vizcarra, J. A., Sturchio, A., Dwivedi, A. K., Keeling, E. G., Patel, D., Mishra, M., Farooqi, A. M., Merola, A., Fasano, A. A., et al. (2020) · Journal of Neurology · doi:10.1007/s00415-020-09892-3 · Cited by 18
Zarkali, A., Hannaway, N., McColgan, P., Heslegrave, A., Veleva, E., Laban, R., Zetterberg, H., Lees, A. J., Fox, N. C., & Weil, R. S. (2024) · Brain Communications · doi:10.1093/braincomms/fcae130 · Cited by 18
Self-citationThe role of disease duration and severity on novel clinical subtypes of Parkinson disease
Erro, R., Picillo, M., Scannapieco, S., Cuoco, S., Pellecchia, M. T., & Barone, P. (2020) · Parkinsonism & Related Disorders · doi:10.1016/j.parkreldis.2020.03.013 · Cited by 17
Emergence of directional bias in tau deposition from axonal transport dynamics
Torok, J., Maia, P. D., Verma, P., Mezias, C., & Raj, A. (2021) · PLoS Computational Biology · doi:10.1371/journal.pcbi.1009258 · Cited by 18
Park, J., Park, K. M., Jo, G., Lee, H., Choi, B. S., Shin, K. J., Ha, S.-Y., Park, S.-H., Lee, H.-J., & Kim, H. Y. (2020) · Parkinsonism & Related Disorders · doi:10.1016/j.parkreldis.2020.10.044 · Cited by 16
Nigral neuropathology of Parkinson’s motor subtypes coincide with circuitopathies: a scoping review
Boonstra, J. T., McGurran, H., Temel, Y., & Jahanshahi, A. (2022) · Brain Structure and Function · doi:10.1007/s00429-022-02531-9 · Cited by 16
Charting Disease Trajectories from Isolated REM Sleep Behavior Disorder to Parkinson's Disease
Di Folco, C., Couronné, R., Arnulf, I., Mangone, G., Leu‐Semenescu, S., Dodet, P., Vidailhet, M., Corvol, J., Lehéricy, S., & Durrleman, S. (2024) · Movement Disorders · doi:10.1002/mds.29662 · Cited by 16
Metabolic Dysfunction in Parkinson’s Disease: Unraveling the Glucose–Lipid Connection
Sian‐Hülsmann, J., Riederer, P. F., & Michel, T. M. (2024) · Biomedicines · doi:10.3390/biomedicines12122841 · Cited by 17
Domotics, Smart Homes, and Parkinson’s Disease
Simonet, C., & Noyce, A. J. (2021) · Journal of Parkinson s Disease · doi:10.3233/jpd-202398 · Cited by 26
Simulating the progression of brain structural alterations in Parkinson’s disease
Park, C.-H., Shin, N., Yoo, S., Seo, H., Yoon, U., Yoo, J.-Y., Ahn, K. J., & Kim, J. (2022) · npj Parkinson s Disease · doi:10.1038/s41531-022-00349-0 · Cited by 15
Kim, H., Park, C., Kim, J., Jang, S., & Lee, H. K. (2024) · IEEE Access · doi:10.1109/access.2024.3405009 · Cited by 17
Joza, S., Camicioli, R. M., & Ba, F. (2019) · Canadian Journal of Neurological Sciences / Journal Canadien des Sciences Neurologiques · doi:10.1017/cjn.2019.287 · Cited by 15
Dream Content Predicts Motor and Cognitive Decline in Parkinson's Disease
Otaiku, A. I. (2021) · Movement Disorders Clinical Practice · doi:10.1002/mdc3.13318 · Cited by 15
Vinding, M. C., Waldthaler, J., Eriksson, A., Manting, C. L., Ferreira, D., Ingvar, M., Svenningsson, P., & Lundqvist, D. (2024) · npj Parkinson s Disease · doi:10.1038/s41531-024-00669-3 · Cited by 29
Clinical classification systems and long-term outcome in mid- and late-stage Parkinson’s disease
Ygland, E., & Puschmann, A. (2021) · npj Parkinson s Disease · doi:10.1038/s41531-021-00208-4 · Cited by 14
Subtyping of early-onset Parkinson’s disease using cluster analysis: A large cohort study
Zhou, Z., Zhou, X., Xiang, Y., Zhao, Y., Pan, H., Wu, J., Xu, Q., Chen, Y., Sun, Q., Wu, X., et al. (2022) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2022.1040293 · Cited by 14
Vinding, M. C., Eriksson, A., Manting, C. L., Waldthaler, J., Ferreira, D., Ingvar, M., Svenningsson, P., & Lundqvist, D. (2021) · medRxiv · doi:10.1101/2021.06.27.21259592 · Cited by 14
New Perspectives of Deep Brain Stimulation Indications for Parkinson’s Disease: A Critical Review
Barbosa, R. M. G., Soares, M. C., Portela, D. M. M. C., Guimarães, T. G., & Cury, R. G. (2024) · Brain Sciences · doi:10.3390/brainsci14070638 · Cited by 13
Unsupervised clustering of dopamine transporter PET imaging discovers heterogeneity of parkinsonism
Suh, M., Im, J. H., Choi, H., Kim, H., Cheon, G. J., & Jeon, B. (2020) · Human Brain Mapping · doi:10.1002/hbm.25155 · Cited by 13
Probing the Pre-diagnostic Phase of Parkinson's Disease in Population-Based Studies
Dommershuijsen, L. J., Boon, A. J. W., & Ikram, M. K. (2021) · Frontiers in Neurology · doi:10.3389/fneur.2021.702502 · Cited by 13
A novel multi-task linear mixed model for smartphone-based telemonitoring
Yoon, H., & Gaw, N. B. (2020) · Expert Systems with Applications · doi:10.1016/j.eswa.2020.113809 · Cited by 13
Disease progression subtypes of Parkinson’s disease based on milestone events
Chen, S., Wang, M., Shao, J.-Y., Yang, H., Zhang, H., & Zhang, J. (2024) · Journal of Neurology · doi:10.1007/s00415-024-12645-1 · Cited by 12
Gait Analysis with Wearables Is a Potential Progression Marker in Parkinson’s Disease
Zhu, S., Wu, Z., Wang, Y., Jiang, Y., Gu, R., Zhong, M., Jiang, X., Shen, B., Zhu, J., Yan, J., et al. (2022) · Brain Sciences · doi:10.3390/brainsci12091213 · Cited by 12
Predictors of anxiety in Parkinson’s disease: results from a 3-year longitudinal cohort study
Gibson, J. S., Flanigan, J. L., Patrie, J. T., Dalrymple, W. A., & Harrison, M. B. (2022) · Neurological Sciences · doi:10.1007/s10072-022-06427-8 · Cited by 12
Bispo, D. P. C. F., Lins, C. C. D. S. A., Hawkes, K. L., Tripp, S., & Khoo, T. K. (2024) · Geriatrics · doi:10.3390/geriatrics9040094 · Cited by 17
Distinct progression patterns across Parkinson disease clinical subtypes
Myers, P. S., Jackson, J. J., Clover, A. K., Lessov‐Schlaggar, C. N., Foster, E. R., Maiti, B., Perlmutter, J. S., & Campbell, M. C. (2021) · Annals of Clinical and Translational Neurology · doi:10.1002/acn3.51436 · Cited by 11
Laryngeal symptoms related to motor phenotypes in Parkinson's disease: A systematic review
Thijs, Z., & Dumican, M. (2023) · Laryngoscope Investigative Otolaryngology · doi:10.1002/lio2.1112 · Cited by 11
Low soluble amyloid-β 42 is associated with smaller brain volume in Parkinson's disease
Espay, A. J., Lafontant, D.-E., Poston, K. L., Caspell‐Garcia, C., Marsili, L., Cho, H. R., McDaniel, C., Kim, N., Coffey, C. S., Mahajan, A., et al. (2021) · Parkinsonism & Related Disorders · doi:10.1016/j.parkreldis.2021.10.010 · Cited by 11
Sejda, A., Wierzba‐Bobrowicz, T., Adamek, D., Gulczyński, J., Michalak, S., Grajkowska, W., & Iżycka‐Świeszewska, E. (2021) · Neurologia i Neurochirurgia Polska · doi:10.5603/pjnns.a2021.0088 · Cited by 10
Role of rodent models in advancing precision medicine for Parkinson's disease
Simons, E., & Fleming, S. M. (2023) · Handbook of clinical neurology · doi:10.1016/b978-0-323-85555-6.00002-3 · Cited by 10
Chen, Z., He, C., Zhang, P., Cai, X., Li, X., Huang, W., Huang, S.-F., Cai, M., Wang, L., Zhan, P., et al. (2024) · Brain Imaging and Behavior · doi:10.1007/s11682-024-00862-1 · Cited by 10
Future Perspectives of NMDAR in CNS Disorders
Capó, T., Rebassa, J. B., Raïch, I., Lillo, J., Badia, P., Navarro, G., & Reyes‐Resina, I. (2025) · Molecules · doi:10.3390/molecules30040877 · Cited by 12
Chase, B. A., Krüger, R., Pavelka, L., Chung, S. J., Aasly, J. O., Dardiotis, E., Premkumar, A. P., Schoneburg, B., Kartha, N., Aunaetitrakul, N., et al. (2023) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2023.1240971 · Cited by 11
Stability of motor-nonmotor subtype in early-stage Parkinson’s disease
Xiao, Y., Wei, Q., Ou, R., Hou, Y., Zhang, L., Liu, K., Lin, J., Yang, T., Jiang, Q., & Shang, H. (2022) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2022.1040405 · Cited by 9
Lamotte, G. J., & Singer, W. (2023) · Handbook of clinical neurology · doi:10.1016/b978-0-323-98817-9.00032-6 · Cited by 9
Twenty-Three-Year Mortality in Parkinson’s Disease: A Population-Based Prospective Study (NEDICES)
Benito-Rodríguez, C. M., Bermejo‐Pareja, F., García, Á. B., Lapeña-Motilva, J., & Benito‐León, J. (2025) · Journal of Clinical Medicine · doi:10.3390/jcm14020498 · Cited by 9
Espay, A. J., & Stecher, B. (2020) · Cambridge University Press eBooks · doi:10.1017/9781108888202 · Cited by 10
Tang, K., Wan, M., Zhang, H., Zhang, Q., Yang, Q., Chen, K., Wang, N., Zhang, D., Qiu, W., & Ma, C. (2020) · Cell and Tissue Banking · doi:10.1007/s10561-020-09849-w · Cited by 8
Nabizadeh, F., Sodeifian, F., & Pirahesh, K. (2022) · Neurological Sciences · doi:10.1007/s10072-022-06110-y · Cited by 8
Chen, X., He, C., Ma, J., Yang, R., Qi, Q., Gao, Z., Du, T., Zhang, P., Li, Y., Cai, M., et al. (2024) · CNS Neuroscience & Therapeutics · doi:10.1111/cns.14918 · Cited by 8
Conti, M., Mascioli, D., Simonetta, C., Ferrari, V., Bissacco, J., Bagetta, S., Carparelli, F., Bernardini, S., Giuliano, F. D., Marchionni, E., et al. (2025) · Neurology · doi:10.1212/wnl.0000000000214449 · Cited by 10
Fox, S. H., Luca, D. G. D., Postuma, R. B., Bhidayasiri, R., Cardoso, F., Kovács, G. G., Katzenschlager, R., & Trenkwalder, C. (2025) · npj Parkinson s Disease · doi:10.1038/s41531-025-01206-6 · Cited by 8
Bowring, F., Welch, J., Woodward, C., Lo, C., Lawton, M., Sulzer, P., Hanff, A.-M. R., Krüger, R., Liepelt‐Scarfone, I., & Hu, M. T. (2022) · BMJ Open · doi:10.1136/bmjopen-2021-049530 · Cited by 8
Disease-modifying vs symptomatic treatments: Splitting over lumping
Duque, K. R., Vizcarra, J. A., Hill, E. J., & Espay, A. J. (2023) · Handbook of clinical neurology · doi:10.1016/b978-0-323-85555-6.00020-5 · Cited by 9
Brain connectivity for subtypes of parkinson’s disease using structural MRI
Samantaray, T., Saini, J. S., Pal, P. K., & Gupta, C. N. (2024) · Biomedical Physics & Engineering Express · doi:10.1088/2057-1976/ad1e77 · Cited by 8
A Clinicopathologic Study of Movement Disorders in Frontotemporal Lobar Degeneration
Pablo‐Fernández, E. D., González‐Herrero, B., Santacruz, D. M. C., Rossor, M. N., Schott, J. M., Lashley, T., Holton, J. L., Fox, N. C., Révész, T., Warren, J. D., et al. (2020) · Movement Disorders · doi:10.1002/mds.28356 · Cited by 10
Self-citationDeterminants of quality of life in Parkinson’s disease: a perspective of novel clinical subtypes
Fan, Y., Zhang, M., Liang, X., Shen, B., Xu, Z., Li, S., Hu, T., Wu, B., Zhao, J., Sun, Y., et al. (2021) · Annals of Clinical and Translational Neurology · doi:10.1002/acn3.51475 · Cited by 8
Hou, Y., Zhang, L., Ou, R., Wei, Q., Gu, X., Liu, K., Lin, J., Yang, T., Xiao, Y., Gong, Q., et al. (2022) · Human Brain Mapping · doi:10.1002/hbm.26110 · Cited by 8
Models of precision medicine for neurodegeneration
Espay, A. J. (2023) · Handbook of clinical neurology · doi:10.1016/b978-0-323-85538-9.00009-2 · Cited by 8
Mitchell, K. T., Younce, J. R., Norris, S. A., Tabbal, S. D., Dowling, J. L., Rich, K. M., Perlmutter, J. S., & Ushe, M. (2020) · Operative Neurosurgery · doi:10.1093/ons/opaa049 · Cited by 8
Prediction of Parkinson’s disease by transcranial sonography-based deep learning
Ding, C. W., Ren, Y. K., Wang, C. S., Zhang, Y. C., Zhang, Y., Yang, M., Mao, P., Sheng, Y. J., Chen, X. F., & Liu, C. (2023) · Neurological Sciences · doi:10.1007/s10072-023-07154-4 · Cited by 7
Fabrizio, C., Termine, A., & Caltagirone, C. (2025) · Journal of Central Nervous System Disease · doi:10.1177/11795735241286821 · Cited by 8
Advances in gait research related to Alzheimer’s disease
Yan, S., Yun, X., Liu, Q., Hong, Z., Chen, Y., & Zhang, S. (2025) · Frontiers in Neurology · doi:10.3389/fneur.2025.1548283 · Cited by 8
α‐Synuclein‐Related Mitochondria‐Nrf2 Dysfunction in Parkinson's Disease Olfactory Mucosa
Maftei, D., Certo, M. G. D., Maurizi, R., Veltri, F., Rosina, M., Bissacco, J., Mascioli, D., Bovenzi, R., Simonetta, C., Mancini, M., et al. (2025) · Annals of Neurology · doi:10.1002/ana.27292 · Cited by 7
Incidence and outcomes of head injuries in people with and without Parkinson disease
Ilmaniemi, S., Tolppanen, A., Herukka, S., Hartikainen, P. H., & Hartikainen, S. A. (2023) · European Journal of Neurology · doi:10.1111/ene.15782 · Cited by 7
Predicting the Prognosis of Multiple System Atrophy Using Cluster and Principal Component Analysis
Du, J., Cui, S., Huang, P., Gao, C., Zhang, P., Liu, J., Li, H., Huang, M., Shen, X., Liu, Z., et al. (2023) · Journal of Parkinson s Disease · doi:10.3233/jpd-225127 · Cited by 7
Park, M., & Lee, Y. (2023) · Neurology Genetics · doi:10.1212/nxg.0000000000200115 · Cited by 7
Development and Validation of a Fall Questionnaire for Patients with Parkinson's Disease
Frank, A. K., Bendig, J., Finkbeiner, S., Hähnel, T., Schnalke, N., Feige, T., Reichmann, H., & Falkenburger, B. H. (2022) · Movement Disorders Clinical Practice · doi:10.1002/mdc3.13515 · Cited by 6
Developing personalized treatment strategies for Parkinson’s disease based on disease subtypes
Hey, G. E., Eisinger, R. S., Guarín, D. L., Safarpour, D., Rodríguez‐Violante, M., & Ramirez‐Zamora, A. (2025) · Expert Review of Neurotherapeutics · doi:10.1080/14737175.2025.2552784 · Cited by 7
Yan, S., Sahoo, A., Zerenner, T., MAREK, K. L., Sommerauer, M., Oertel, W. H., Hu, M. T., & Tofaris, G. K. (2025) · Annals of Neurology · doi:10.1002/ana.78109 · Cited by 6
Olszewska, D. A., & Lang, A. E. (2023) · Handbook of clinical neurology · doi:10.1016/b978-0-323-85538-9.00005-5 · Cited by 6
Anticipating Tomorrow: Tailoring Parkinson's Symptomatic Therapy Using Predictors of Outcome
Postuma, R. B., Weintraub, D. A., Simuni, T., Rodríguez‐Violante, M., Leentjens, A. F. G., Hu, M. T., Espay, A. J., Erro, R., Dujardin, K., Bohnen, N. I., et al. (2024) · Movement Disorders Clinical Practice · doi:10.1002/mdc3.14089 · Cited by 6
Exploring the potential of MFG-E8 in neurodegenerative diseases
Li, D., Wang, R., Lu, W., & Ma, Y. (2024) · Critical Reviews in Food Science and Nutrition · doi:10.1080/10408398.2024.2417800 · Cited by 8
Wilful pathogens provoke a gut feeling in Parkinson’s disease
Sian‐Hülsmann, J. (2021) · Journal of Neural Transmission · doi:10.1007/s00702-021-02448-3 · Cited by 6
Vallelonga, F., Valente, M., Tangari, M. M., Covolo, A., Milazzo, V., Stefano, C. D., Sobrero, G., Giudici, M., Milan, A., Veglio, F., et al. (2024) · Clinical Autonomic Research · doi:10.1007/s10286-024-01030-7 · Cited by 6
Association between striatal amyloid deposition and motor prognosis in Parkinson's disease
Park, M., Kim, H. J., Baik, K., Na, H. K., Lee, Y., Yoon, S. H., Jeong, S. H., Chung, S. J., Shin, H., Lyoo, C. H., et al. (2024) · European Journal of Neurology · doi:10.1111/ene.16364 · Cited by 6
Review of Artificial Intelligence for Clinical Use in Alzheimer's Disease and Related Dementias
Breithaupt, A. G., Tang, A., Paolillo, E. W., Bibars, M., Johnson, E. C. B., Saloner, R., Possin, K. L., Windon, C. C., Hill-Jarrett, T. G., Giorgio, J., et al. (2026) · Seminars in Neurology · doi:10.1055/a-2744-9871 · Cited by 6
Beyond Pathology: α‐Synuclein Homeostasis and Three Principles to Guide Research
Espay, A. J., & Lees, A. J. (2025) · Movement Disorders Clinical Practice · doi:10.1002/mdc3.70400 · Cited by 5
Self-citationFraza, C., Bučková, B. R., Johansson, M. E., Helmich, R. C. G., Marquand, A. F., & Beckmann, C. F. (2025) · Scientific Reports · doi:10.1038/s41598-025-20484-x · Cited by 5
Hasnain, N., Arif, T. B., Shafaut, R., Zakaria, F., Fatima, S. Z., & Haque, I. U. (2022) · Wiener Medizinische Wochenschrift · doi:10.1007/s10354-022-00941-2 · Cited by 5
Méresse, S., Larrigaldie, V., Oummadi, A., de Concini, V., Morisset‐Lopez, S., Reverchon, F., Menuet, A., Montécot, C., & Mortaud, S. (2022) · Toxicology · doi:10.1016/j.tox.2022.153358 · Cited by 6
Couto, B., Sousa, M., González-Latapí, P., McArthur, E., Lang, A. E., Chen‐Plotkin, A. S., & Marras, C. (2023) · Canadian Journal of Neurological Sciences / Journal Canadien des Sciences Neurologiques · doi:10.1017/cjn.2023.281 · Cited by 5
Li, X., Luo, M., Xu, H., Jia, L., Liang, Y., Xu, Q., & Wang, Y. (2024) · Frontiers in Immunology · doi:10.3389/fimmu.2024.1377409 · Cited by 5
Current clinical approaches in neurodegenerative diseases
Gago, M. F., Machado, Á. S., & Rocha, S. (2020) · Elsevier eBooks · doi:10.1016/b978-0-12-818084-6.00004-0 · Cited by 5
Kitazaki, Y., Ikawa, M., Yamaguchi, T., Enomoto, S., Shirafuji, N., Yamamura, O., Tsujikawa, T., Okazawa, H., Kimura, H., Nakamoto, Y., et al. (2022) · Neuroradiology · doi:10.1007/s00234-022-03085-7 · Cited by 5
Toward biomarker-based clinical subtyping of Parkinson disease
Lamotte, G. J., & Becker, B. (2020) · Neurology · doi:10.1212/wnl.0000000000010496 · Cited by 5
Woo, K. A., Yoon, E. J., Kim, S., Kim, H., Kim, R., Jin, B., Lee, S., Park, H., Nam, H., Kim, Y. K., et al. (2024) · Movement Disorders · doi:10.1002/mds.30031 · Cited by 4
Takeda, K., Fujishiro, H., Torii, Y., Sekiguchi, H., Arafuka, S., Habuchi, C., Miwa, A., Ozaki, N., Yoshida, M., Iritani, S., et al. (2025) · Psychiatry and Clinical Neurosciences · doi:10.1111/pcn.13814 · Cited by 4
Bioactive Compounds of the Genus Spirulina Can Prevent the Progression of Neurological Diseases
Elkader, H. A. E. A., Essawy, A. E., & Al‐Shami, A. S. (2024) · Neurochemical Journal · doi:10.1134/s1819712424010057 · Cited by 4
The association of motor reserve and clinical progression in Parkinson’s disease
Bai, X., Shiwei, Z., Li, Q., Guo, T., Guan, X., Qian, A., Chen, S., Zhou, R., Cheng, Y., Chen, H., et al. (2024) · NeuroImage Clinical · doi:10.1016/j.nicl.2024.103704 · Cited by 4
Deep brain stimulation outcomes in the malignant end of Parkinson's disease spectrum
Artusi, C. A., Romagnolo, A., Imbalzano, G., Montanaro, E., Zibetti, M., Rizzone, M. G., & Lopiano, L. (2021) · Parkinsonism & Related Disorders · doi:10.1016/j.parkreldis.2021.03.017 · Cited by 4
Jun, P., Zhao, H., Kwon, O., & Jang, J.-H. (2022) · Evidence-based Complementary and Alternative Medicine · doi:10.1155/2022/4777849 · Cited by 4
Staging Parkinson's disease according to the MNCD classification correlates with caregiver burden
Santos‐García, D., Fonticoba, T. D. D., Bartolomé, C. C., Painceiras, M. J. F., Díaz, I. G., Alvarado, M. C. Í., Paz, J. M., Jesús, S., Cosgaya, M., Caldentey, J. G., et al. (2023) · Brain and Behavior · doi:10.1002/brb3.3295 · Cited by 4
Associations of serum neuromarkers with clinical features of Parkinson’s disease
Никитина, М. А., Koroleva, E. S., Brazovskaya, N. G., Boyko, A. S., Levchuk, L. A., Ivanova, S. А., & Alifirova, V. M. (2024) · S S Korsakov Journal of Neurology and Psychiatry · doi:10.17116/jnevro2024124041145 · Cited by 4
Metadata
- Authors
- De Pablo-Fernández, E., Lees, A. J., Holton, J. L., & Warner, T. T.
- Affiliations
- Reta Lila Weston Institute of Neurological Studies, University College London Queen Square Institute of Neurology, London, England
- National Hospital for Neurology and Neurosurgery (GB)
- Corresponding author
- Warner, Thomas T.
- Venue
- JAMA Neurology
- Publisher
- American Medical Association (AMA)
- Published
- 2019-04-01
- Volume
- 76
- Issue
- 4
- Pages
- 470
- ISSN
- 2168-6149 (ISSN-L)
- PMC
- PMC6459129
- OpenAlex
- W2909700430
- Cited by
- 332
- References
- 31
- Citations by year
- 2026: 23 · 2025: 53 · 2024: 45 · 2023: 42 · 2022: 46 · 2021: 39 · 2020: 63 · 2019: 20
- FWCI
- 28.42
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- JAMA Neurology (publishedVersion)
- Europe PMC (PubMed Central) (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- UCL Discovery (University College London) (submittedVersion)
- Funders
- Medical Research Council (MR/L023784/2, MR/L023784/1)
- Topics
- Health Sciences › Medicine › Clinical Neurology › Parkinson's Disease Mechanisms and Treatments
- Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
- Health Sciences › Medicine › Clinical Neurology › Deep Brain Stimulation and Movement Disorders
- Keywords
- Parkinson's disease, clinical subtypes, prognosis, disease progression, survival, Lewy body pathology, rapid eye movement sleep behavior disorder, dementia, wheelchair dependence, nursing home admission, age at death, autonomic dysfunction, cognitive function, brain donation
- MeSH terms
- Aged, Autonomic Nervous System Diseases, Autopsy, Brain, Female, Humans, Male, Middle Aged, Parkinson Disease, Prognosis, Retrospective Studies, Severity of Illness Index, Survival Rate, Proportional Hazards Models, Lewy Bodies, Neurofibrillary Tangles, Age of Onset, Disease Progression, REM Sleep Behavior Disorder, Plaque, Amyloid, Cognitive Dysfunction
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
